Amwell exceeded its Q4 2025 financial guidance with total revenue of $55.3 million. The company reported a net loss of ($25.2) million and adjusted EBITDA of ($10.3) million, both showing improvement from the third quarter of 2025. The focus on its Technology Enabled Care platform contributed to strong market validation and contract renewals.

Amwell delivered a strong Q1 2025, with total revenue reaching $66.8 million and significant improvement in net loss and Adjusted EBITDA. The company advanced its strategic initiatives, including progress with the Military Health System and improvements in revenue quality and cost alignment, moving closer to its goal of achieving cash flow breakeven from operations in 2026.

Amwell reported a total revenue of $71.0 million for Q4 2024, with a net loss of ($44.6) million. The company achieved a gross margin of 48% and an adjusted EBITDA of ($22.8) million, showing an improvement compared to the previous quarter.

Amwell reported a total revenue of $61.0 million for Q3 2024. The company is focused on aligning its cost structure and building its growth organization to deliver high quality, higher margin revenue. They are also underway in delivering the successful deployment of the Defense Heath Agency’s Digital First Initiative for the Military Health System.

Amwell reported Q2 2024 financial results, showing progress in U.S. Military Health System deployment and improved adjusted EBITDA outlook due to cost alignment efforts. The company reiterated its 2024 revenue and visit guidance.

Amwell reported a total revenue of $59.5 million for Q1 2024. The company is focused on deploying its solution for the Military Health System and migrating visit volume onto its Converge platform. They are also optimizing their cost structure with the aim to achieve profitable growth.

Amwell reported Q4 2023 total revenue of $70.7 million, with subscription revenue at $27.3 million and AMG visit revenue at $32.1 million. The company's gross margin was 34%, and it reported a net loss of $50.0 million. Total visits reached 1.6 million, with 52% occurring on the Converge platform. The company is focused on achieving profitability.

Amwell reported Q3 2023 financial results, with total revenue of $61.9 million. The company's net loss was $137.1 million, which included non-cash goodwill impairment charges of $78.9 million. Adjusted EBITDA improved to ($38.5) million. The company reached its goal of 50% of visits on Converge one quarter ahead of schedule.

Amwell reported a revenue of $62.4 million for Q2 2023. The company's net loss was $93.5 million, which included non-cash goodwill impairment charges of $27.3 million. Adjusted EBITDA was ($45.3) million. Total visits were 1.5 million, with 43% of visits on Converge.

Amwell reported a total revenue of $64.0 million for Q1 2023. The company's net loss was ($398.5) million, which includes a non-cash goodwill impairment charge of $330.3 million. Adjusted EBITDA was ($44.6) million. Total visits were 1.7 million, with Converge visits growing to 36% of the total.

Amwell reported a 9% increase in total revenue for Q4 2022 compared to Q4 2021, achieving $79.2 million. The company focused on the Converge platform and client migrations.

Amwell reported an 11% increase in total revenue to $69.2 million for Q3 2022, driven by subscription revenue growth of 19%. The company's gross margin was 40%. Net loss was ($70.6) million. Adjusted EBITDA improved to ($41.9) million. The company refines its guidance as follows: revenue in the lower end of previously provided range of $275 and $285 million and a new Adjusted EBITDA range of between ($180) million and ($190) million.

Amwell reported a 7% increase in total revenue for Q2 2022, reaching $64.5 million compared to $60.2 million in Q2 2021. The company saw growth in both subscription revenue and AMG visit revenue. They are reiterating their 2022 outlook with revenue expected between $275 and $285 million.

Amwell reported a revenue of $64.2 million for Q1 2022, compared to $57.6 million in Q1 2021. The company's gross margin was 42.8%, up from 38.0% in the same period last year. Net loss increased to ($70.3) million, compared to ($39.8) million in the prior year. The company is reiterating its 2022 revenue outlook between $275 and $285 million.

American Well's Q4 2021 saw a revenue increase to $72.8 million compared to $60.4 million in the same period last year. The company's active providers reached approximately 91,000. However, the net loss remained significant at ($47.9) million.

Amwell's total revenue was $62.2 million, with a gross margin of 43.5%. The company had a net loss of $50.9 million and an adjusted EBITDA of ($31.5) million. Total active providers were approximately 80,000 and total visits were approximately 1.4 million.

Amwell reported a slight increase in revenue and an expansion of gross margins, but experienced a decrease in total visits. The company is adjusting its visit forecast downwards due to the resurgence of mask mandates and other factors related to the COVID-Delta variant.

Amwell's Q1 2021 results showed a revenue increase of 7% year-over-year to $57.6 million. Total active providers increased by 240% to approximately 81,000, and total visits increased by 120% to 1.6 million. The company's net loss was $39.8 million, and adjusted EBITDA was $(26.4) million, impacted by increased R&D investment in the Converge technology platform.

Amwell reported a strong Q4 2020, marked by a 34% increase in revenue to $60.4 million and a 300% increase in total visits to 1.6 million. The company highlighted the rapid evolution of telehealth, driven by the pandemic, into a mission-critical digital care delivery infrastructure. Amwell is accelerating investments in its technology platform to meet the post-pandemic market's demand for comprehensive telehealth solutions.

Amwell announced strong Q3 2020 results, demonstrating significant growth in revenue, visits, and active providers. The company's platform is playing an increasingly important role in meeting the demand for telehealth infrastructure.